Olr363 inhibitors represent a specialized class of chemical compounds primarily characterized by their interaction with the Olr363 receptor, a specific olfactory receptor type in the G protein-coupled receptor (GPCR) superfamily. Olr363, like other olfactory receptors, is integral to the detection and transduction of chemical signals, primarily volatile molecules, into neural signals that contribute to the sense of smell. The inhibitors of Olr363 are designed to modulate the activity of this receptor by preventing its activation by natural ligands, thereby altering the signal transduction pathways that are initiated upon receptor-ligand binding. This class of inhibitors often comprises molecules with structural features that allow them to competitively or non-competitively bind to the active site or allosteric sites of Olr363, thereby hindering the receptor's ability to interact with its natural agonists.
Chemically, Olr363 inhibitors can vary widely in their molecular structure, but they generally share certain characteristics that enable them to effectively target the receptor. These inhibitors may possess hydrophobic moieties that facilitate interaction with the hydrophobic binding pocket of the Olr363 receptor. Additionally, many Olr363 inhibitors are designed with specific functional groups that can engage in hydrogen bonding or van der Waals interactions with key amino acid residues in the receptor's binding domain. The efficacy and specificity of these inhibitors are often influenced by their molecular conformation, which must complement the three-dimensional structure of the Olr363 receptor. The development and study of Olr363 inhibitors typically involve a deep understanding of receptor-ligand interactions, binding affinities, and the structural dynamics of the receptor, making them a fascinating subject of study within the field of chemical biology and receptor chemistry.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual EGFR and HER2 inhibitor, potentially disrupts signaling in certain cancers. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
mTOR inhibitor, may limit cell growth and proliferation in various cancers. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Multi-kinase inhibitor, could affect cell proliferation and angiogenesis in tumors. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
EGFR inhibitor, potentially effective in non-small cell lung carcinoma. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, may be effective in T790M-positive lung cancer. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, potentially effective in colorectal cancer and GIST. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor, could inhibit cell proliferation in melanoma with BRAF mutations. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
BTK inhibitor, potentially effective in certain B-cell malignancies. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $178.00 $648.00 $1657.00 | 3 | |
Multi-kinase inhibitor, might affect thyroid and renal cell carcinoma. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
MET, VEGFR2, RET inhibitor, could be effective in medullary thyroid cancer. | ||||||